Please use this identifier to cite or link to this item:
|Title:||What do antineutrophil cytoplasmic antibodies (ANCA) tell us?|
|Authors:||Savige, Judy A;Pollock, Wendy;Trevisin, Michelle|
|Affiliation:||Department of Medicine, The Northern Hospital, Austin Health/Northern Health, University of Melbourne, Epping, Vic. 3076, Australia. firstname.lastname@example.org|
|Citation:||Best Practice & Research. Clinical Rheumatology; 19(2): 263-76|
|Abstract:||Antineutrophil cytoplasmic antibodies (ANCA) are autoantibodies directed against antigens found in the cytoplasmic granules of neutrophils and monocytes. ANCA testing is usually performed to help diagnose or exclude Wegener's granulomatosis and microscopic polyangiitis. The three most commonly used assays are indirect immunofluorescence (IIF) and the direct and 'capture' enzyme-linked immunosorbent assays (ELISAs) for ANCA directed against proteinase 3 (PR3) and myeloperoxidase (MPO). Although the International Consensus Statement for Testing and Reporting ANCA recommends that all sera are screened for ANCA by IIF and that IIF-positivity is confirmed by direct ELISAs, some laboratories test by direct ELISA alone, others screen with direct ELISA and confirm positive sera by IIF, and a few use capture ELISAs. This chapter discusses the various forms of vasculitis associated with ANCA, the usefulness of each of the ANCA assays and how ANCA testing can be used in the management of patients with small-vessel vasculitis.|
|Internal ID Number:||15857795|
|Subjects:||Antibodies, Antineutrophil Cytoplasmic.blood.diagnostic use|
Sensitivity and Specificity
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.